Clinical Trials on Mucopolysaccharidosis IV A in Belgium

Total 278 results

BioMarin Pharmaceutical
ICON plc

Completed

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)

Mucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVA

United States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
Universitaire Ziekenhuizen KU Leuven

Completed

SecurAcath Versus Statlock for PICC Securement (SecurAstaP)

Patients With Any Condition Who Need a PICC for IV Therapy

Belgium
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
BioMarin Pharmaceutical

Completed

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

United States, France, Australia, Germany, Ireland, Austria, Belgium, Italy, Lithuania, Netherlands, Portugal, Sweden, United Kingdom
Genzyme, a Sanofi Company

Recruiting

Mucopolysaccharidosis I (MPS I) Registry

Mucopolysaccharidosis I (MPS I)

Croatia, United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Hong Kong, India, Indonesia, Korea, Republic of, Kuwait, Lebanon, Malaysia, Netherlands, Pakistan, Philippines, Poland, Saudi Arabia, Singapore, Slovaki... and more
Denali Therapeutics Inc.

Recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (COMPASS)

Mucopolysaccharidosis II

United States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Brazil, Colombia
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Completed

Switch Timely to Oral Medication (STORM)

IV Oral Switch | Appropriateness Review

Belgium
Erasme University Hospital

Completed

Minimal Optimal Dose of Sugammadex in Elective Surgery

Time of a TOF Ratio >0,9

Belgium
University Hospital, Ghent

Completed

Primary Ceramic-on-Ceramic Total Hip Replacement Versus Metal-on-Metal Hip Resurfacing in Young Active Patients

Indications for a Total Hip Prosthesis

Belgium
University Hospital, Ghent

Completed

Primary Birmingham Hip Resurfacing Arthroplasty Using a Metal-on-Metal Couple in the Young Active Patient

Indications for a Total Hip Prosthesis

Belgium
University Ghent
Federal Agency for Nuclear Control, Belgium

Completed

Low Dose Effects of X-rays in Pediatric Patients Undergoing a CT Examination. (PedCTBe)

Pediatric Patients Undergoing a Computed Tomography Examination

Belgium
Brugmann University Hospital

Completed

Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?

Elderly Patients With a Solid Tumor

Belgium
AZ-VUB

Unknown

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Belgium
University Hospital, Ghent

Completed

Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation

Children With a Univentricular Heart Undergoing Surgery for Creation of a Fontan Circulation

Belgium
PXL University College

Completed

Feasibility Study of i-ACT in Aged Persons (i-ACT-aged)

Feasibility of a Technology-based System in Aged Person

Belgium
Jules Bordet Institute

Completed

PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

Carcinoma Breast Stage IV

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Predictive Modelling of the Intraoperative Train-of-Four (TOF) Ratio

Analyse Neuromuscular Monitoring for Developing a Model to Predict TOF Ratio During Anesthesia

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy

Haemophilia A | Haemophilia B

Belgium
Comunicare Solutions SA
KU Leuven; Jessa Hospital; Cliniques universitaires Saint-Luc- Université Catholique... and other collaborators

Recruiting

Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support in Patients With HF (BEDICARE-HF)

Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV

Belgium
General Hospital Groeninge

Completed

Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients (CONCEPT)

Cognitive Impairment | Cancer Patients Eligible for a Treatment With Curative Intent

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Hepatitis A

Belgium
Cliniques universitaires Saint-Luc- Université...

Withdrawn

Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy

Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy

Belgium
GlaxoSmithKline

Withdrawn

Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®

Hepatitis A

Belgium
Crucell Holland BV

Completed

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Hepatitis A

Belgium
Universitair Ziekenhuis Brussel

Recruiting

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel)

Melanoma Stage IV | Melanoma Stage III

Belgium
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
KU Leuven

Completed

NMES in Critically Ill Patients (NESCI)

Critically Ill Patients With a Predicted Prolonged ICU Stay

Belgium
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
Universitair Ziekenhuis Brussel
RIZIV

Completed

mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma (DC-MEL)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
Bart Neyns
Vrije Universiteit Brussel

Completed

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
IDEWE Occupational Health Services
GlaxoSmithKline

Unknown

Twinrix Alternative Schedule Study

Antibody Response After Vaccination

Belgium
Brugmann University Hospital

Completed

Prevalence and Screening of Hepatitis C in Belgium in 2015

Hepatitis C

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Universitair Ziekenhuis Brussel

Completed

Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma (GliAvAx)

Recurrent Glioblastoma (WHO-Grade IV Glioma)

Belgium
University Hospital, Ghent
Centre Hospitalier Universitaire Vaudois; University Ghent; Hopital Lariboisière and other collaborators

Completed

PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer (PIPAC-nabpac)

Breast Cancer Stage IV | Peritoneal Carcinomatosis | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Breast Cancer Stage IIIB | Breast Cancer Stage IIIc | Ovarian Cancer Stage IIIB | Stomach Cancer Stage III | Stomach Cancer Stage IV With Metastases | Pancreas Cancer, Stage III | Pancreas Cancer, Stage...

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

Hepatitis C

Belgium
GlaxoSmithKline

Completed

Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline
Region of Wallonia; Public Private Partnership with Institute for Medical Immunology...

Completed

Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

Hepatitis B

Belgium
Hasselt University

Unknown

Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA

Hepatitis C | Drug Use

Belgium

Clinical Trials on Mucopolysaccharidosis IV A in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations